Golden has been acquired by ComplyAdvantage.Read about it here ⟶

List of GlaxoSmithKline patents

Patents where

Current Assignee

Name

GlaxoSmithKline

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 8937071 Compounds as rearranged during transfection (RET) inhibitors	Patent 8937071 was granted and assigned to GlaxoSmithKline on January, 2015 by the United States Patent and Trademark Office.	GlaxoSmithKline	GlaxoSmithKline	United States Patent and Trademark Office	8937071	January 20, 2015
‌ US Patent 9035063 Compounds as rearranged during transfection (RET) inhibitors	Patent 9035063 was granted and assigned to GlaxoSmithKline on May, 2015 by the United States Patent and Trademark Office.	GlaxoSmithKline	GlaxoSmithKline	United States Patent and Trademark Office	9035063	May 19, 2015
‌ US Patent 9789100 Compounds as rearranged during transfection (RET) inhibitors	Patent 9789100 was granted and assigned to GlaxoSmithKline on October, 2017 by the United States Patent and Trademark Office.	GlaxoSmithKline	GlaxoSmithKline	United States Patent and Trademark Office	9789100	October 17, 2017
‌ US Patent 11434032 Modular aseptic production system	Patent 11434032 was granted and assigned to GlaxoSmithKline on September, 2022 by the United States Patent and Trademark Office.		GlaxoSmithKline	United States Patent and Trademark Office	11434032	September 6, 2022
‌ US Patent 10336744 1AP E3 ligase directed proteolysis targeting chimeric molecules	Patent 10336744 was granted and assigned to GlaxoSmithKline on July, 2019 by the United States Patent and Trademark Office.	GlaxoSmithKline	GlaxoSmithKline	United States Patent and Trademark Office	10336744	July 2, 2019
‌ US Patent 10947015 Tamper evident cap assembly	Patent 10947015 was granted and assigned to GlaxoSmithKline on March, 2021 by the United States Patent and Trademark Office.	GlaxoSmithKline	GlaxoSmithKline	United States Patent and Trademark Office	10947015	March 16, 2021
‌ US Patent 8952018 Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors	Patent 8952018 was granted and assigned to GlaxoSmithKline on February, 2015 by the United States Patent and Trademark Office.		GlaxoSmithKline	United States Patent and Trademark Office	8952018	February 10, 2015
‌ US Patent 11353458 Prognostic method	Patent 11353458 was granted and assigned to GlaxoSmithKline on June, 2022 by the United States Patent and Trademark Office.	GlaxoSmithKline	GlaxoSmithKline	United States Patent and Trademark Office	11353458	June 7, 2022
‌ US Patent 11427643 Targeted protein degradation	Patent 11427643 was granted and assigned to GlaxoSmithKline on August, 2022 by the United States Patent and Trademark Office.	GlaxoSmithKline	GlaxoSmithKline	United States Patent and Trademark Office	11427643	August 30, 2022
‌ US Patent 11401334 Combination treatment for cancer with anti-BCMA binding protein and proteosome inhibitor		GlaxoSmithKline	GlaxoSmithKline	United States Patent and Trademark Office	11401334	August 2, 2022
‌ US Patent 11535833 Carboxyesterase biocatalysts		GlaxoSmithKline	GlaxoSmithKline	United States Patent and Trademark Office	11535833	December 27, 2022
‌ US Patent 10358427 Modulators of indoleamine 2,3-dioxygenase	Patent 10358427 was granted and assigned to GlaxoSmithKline on July, 2019 by the United States Patent and Trademark Office.	GlaxoSmithKline	GlaxoSmithKline	United States Patent and Trademark Office	10358427	July 23, 2019
‌ US Patent 8404837 Quinoline derivatives as P13 kinase inhibitors	Patent 8404837 was granted and assigned to GlaxoSmithKline on March, 2013 by the United States Patent and Trademark Office.		GlaxoSmithKline	United States Patent and Trademark Office	8404837	March 26, 2013
‌ US Patent 9187464 TRPV4 antagonists	Patent 9187464 was granted and assigned to GlaxoSmithKline on November, 2015 by the United States Patent and Trademark Office.		GlaxoSmithKline	United States Patent and Trademark Office	9187464	November 17, 2015
‌ US Patent 9670221 Furopyridines as bromodomain inhibitors	Patent 9670221 was granted and assigned to GlaxoSmithKline on June, 2017 by the United States Patent and Trademark Office.		GlaxoSmithKline	United States Patent and Trademark Office	9670221	June 6, 2017
‌ US Patent 10034881 2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors	Patent 10034881 was granted and assigned to GlaxoSmithKline on July, 2018 by the United States Patent and Trademark Office.	GlaxoSmithKline	GlaxoSmithKline	United States Patent and Trademark Office	10034881	July 31, 2018
‌ US Patent 11648717 System and method for moulding a tufted body with a curved outer surface	Patent 11648717 was granted and assigned to GlaxoSmithKline on May, 2023 by the United States Patent and Trademark Office.		GlaxoSmithKline	United States Patent and Trademark Office	11648717	May 16, 2023
‌ US Patent D790686 Housing for an autoinjector	Patent D790686 was granted and assigned to GlaxoSmithKline on June, 2017 by the United States Patent and Trademark Office.	GlaxoSmithKline	GlaxoSmithKline	United States Patent and Trademark Office	D790686	June 27, 2017
‌ US Patent 11566347 Antibody variants	Patent 11566347 was granted and assigned to GlaxoSmithKline on January, 2023 by the United States Patent and Trademark Office.		GlaxoSmithKline	United States Patent and Trademark Office	11566347	January 31, 2023
‌ US Patent 10588891 TRPV4 antagonists	Patent 10588891 was granted and assigned to GlaxoSmithKline on March, 2020 by the United States Patent and Trademark Office.	GlaxoSmithKline	GlaxoSmithKline	United States Patent and Trademark Office	10588891	March 17, 2020
‌ US Patent 9505745 Enhancer of zeste homolog 2 inhibitors	Patent 9505745 was granted and assigned to GlaxoSmithKline on November, 2016 by the United States Patent and Trademark Office.	GlaxoSmithKline	GlaxoSmithKline	United States Patent and Trademark Office	9505745	November 29, 2016
‌ US Patent 10590085 Heterocyclic amides as kinase inhibitors	Patent 10590085 was granted and assigned to GlaxoSmithKline on March, 2020 by the United States Patent and Trademark Office.	GlaxoSmithKline	GlaxoSmithKline	United States Patent and Trademark Office	10590085	March 17, 2020
‌ US Patent 10047115 Cyclic dinucleotides useful for the treatment of inter alia cancer	Patent 10047115 was granted and assigned to GlaxoSmithKline on August, 2018 by the United States Patent and Trademark Office.	GlaxoSmithKline	GlaxoSmithKline	United States Patent and Trademark Office	10047115	August 14, 2018
‌ US Patent 10450288 Hydroxy formamide derivatives and their use	Patent 10450288 was granted and assigned to GlaxoSmithKline on October, 2019 by the United States Patent and Trademark Office.	GlaxoSmithKline	GlaxoSmithKline	United States Patent and Trademark Office	10450288	October 22, 2019
‌ US Patent 10292987 Heterocyclic amides as kinase inhibitors	Patent 10292987 was granted and assigned to GlaxoSmithKline on May, 2019 by the United States Patent and Trademark Office.	GlaxoSmithKline	GlaxoSmithKline	United States Patent and Trademark Office	10292987	May 21, 2019

...

Results per page:

223 results

0 selected

223 results

0 selected